

# Bcl-2-mediated Drug Resistance: Inhibition of Apoptosis by Blocking Nuclear Factor of Activated T Lymphocytes (NFAT)-induced Fas Ligand Transcription

By Rakesh K. Srivastava,\* Carl Y. Sasaki,\* J. Marie Hardwick,<sup>‡</sup> and Dan L. Longo\*

From the \*Laboratory of Immunology, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224-6825; and the <sup>‡</sup>Department of Molecular Biology and Immunology, Johns Hopkins School of Public Health, Baltimore, Maryland 21205

## Summary

Bcl-2 inhibits apoptosis induced by a variety of stimuli, including chemotherapy drugs and glucocorticoids. It is generally accepted that Bcl-2 exerts its antiapoptotic effects mainly by dimerizing with proapoptotic members of the Bcl-2 family such as Bax and Bad. However, the mechanism of the antiapoptotic effects is unclear. Paclitaxel and other drugs that disturb microtubule dynamics kill cells in a Fas/Fas ligand (FasL)-dependent manner; antibody to FasL inhibits paclitaxel-induced apoptosis. We have found that Bcl-2 overexpression leads to the prevention of chemotherapy (paclitaxel)-induced expression of FasL and blocks paclitaxel-induced apoptosis. The mechanism of this effect is that Bcl-2 prevents the nuclear translocation of NFAT (nuclear factor of activated T lymphocytes, a transcription factor activated by microtubule damage) by binding and sequestering calcineurin, a calcium-dependent phosphatase that must dephosphorylate NFAT to move to the nucleus. Without NFAT nuclear translocation, the FasL gene is not transcribed. Thus, it appears that paclitaxel and other drugs that disturb microtubule function kill cells at least in part through the induction of FasL. Furthermore, Bcl-2 antagonizes drug-induced apoptosis by inhibiting calcineurin activation, blocking NFAT nuclear translocation, and preventing FasL expression. The effects of Bcl-2 can be overcome, at least partially, through phosphorylation of Bcl-2. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation, FasL expression, and apoptosis can occur after Bcl-2 phosphorylation.

Key words: Fas ligand • apoptosis • NFAT • Bcl-2 • paclitaxel

Binding of Fas ligand (FasL)<sup>1</sup> or an anti-Fas antibody to Fas (APO-1 or CD-95) causes apoptosis in Fas-bearing cells. Fas is ubiquitously expressed in various cell types (1–3), but the expression of FasL is much more restricted (4–7). Although the expression of FasL was originally considered to be restricted to activated T cells and NK cells, FasL has been identified in other cell types, including Sertoli cells and cells of the eye, liver, and kidney (8). The expression of functional FasL by some tissues contributes to their immune-privileged status by preventing the infiltration of inflammatory leukocytes (9, 10). Recently, constitutive FasL expression has been detected on some tumor cells, indicating that it may function to induce apoptosis in Fas-expressing immune cells when they attempt to enter the tumor (11–14). Moreover, it has been postulated that the Fas/FasL system has an important role in the pathogenesis of many diseases such as hepatitis, insulin-dependent diabetes, cancer, and thyroiditis (Hashimoto's disease) (15–21).

The antiapoptotic gene Bcl-2 protects cancer cells from apoptosis induced by a variety of anticancer agents (22–25). The precise mechanism by which Bcl-2 inhibits drug-induced apoptosis is unknown. Mice in which wild-type Bcl-2 was overexpressed documented extended cell survival rather than increased proliferation and led to an accumulation of lymphocytes that eventually progressed to B and T cell malignancy after subsequent genetic changes (26–28). Loss of function studies that knocked out the Bcl-2 or Bcl-X<sub>L</sub> death suppressors demonstrated the loss of cells from selected lineages (29–31). Although hematopoietic lineages appear to develop normally in the Bcl-2-deficient mice, they are unable to maintain homeostasis of lymphocytes because of excess apoptotic loss of B and T cells. Microtubule-stabilizing agents such as paclitaxel and docetaxel and microtubule-disrupting drugs such as vincristine, vinblastine, and colchicine have antimitotic and apoptosis-inducing activity (24, 25, 32, 33). Recently, screening of a library of phage-displayed peptides identified human Bcl-2 as a paclitaxel-binding protein (34). Paclitaxel induces Bcl-2 phosphorylation and apoptosis in human leukemic, breast, and

<sup>1</sup>Abbreviations used in this paper: L, ligand; NFAT, nuclear factor of activated T lymphocytes; PI, propidium iodide.

prostate cancer cells (24, 25, 35), suggesting that phosphorylation of Bcl-2 may inhibit Bcl-2 function. The regulation of Bcl-2 function by phosphorylation has been demonstrated at the level of formation of Bcl-2–Bax heterodimers. However, it is also possible that Bcl-2 exerts its biological effects in additional protein interactions distinct from those with proapoptotic family members.

A growing body of evidence suggests that the nuclear factor of activated T lymphocytes (NFAT) is expressed in a variety of tissues in addition to lymphocytes (36). To date, NFAT expression or function has been described in several types of nonlymphoid cells, including mast cells (37), endothelial cells (38), vascular smooth muscle cells (39), and neuronal cells (40). The messenger RNAs of distinct NFAT isoforms are expressed in a tissue-specific manner (41). Linette et al. (41a) have documented a regulatory interaction between Bcl-2 expression and NFAT activation. Thus, it is possible that NFAT regulates the transcription of genes involved in apoptosis and that antiapoptotic Bcl-2 family members act in part by interfering with NFAT-induced gene transcription.

One candidate proapoptotic gene that is regulated by NFAT is FasL. Transcription of the FasL gene is regulated at least in part by an interaction of NFAT proteins with the FasL promoter (42–44). Transcription mediated by NFAT is regulated tightly in response to second messengers such as calcium. Increased intracellular  $Ca^{2+}$  stimulates calcineurin-dependent dephosphorylation of cytoplasmic NFAT, leading to its nuclear translocation (45). T cell activation was found to induce NFAT binding to the FasL enhancer (45). Thus, it is possible that Bcl-2 mediates its antiapoptotic effects not only by forming heterodimers with proapoptotic Bcl-2 family members but also through antagonism of NFAT activation.

In this study, we examine the intracellular mechanisms by which Bcl-2 inhibits apoptosis induced by microtubule-damaging drugs (paclitaxel, vincristine, and vinblastine) in Jurkat T lymphocytes and breast carcinoma cells. We demonstrate that expression of FasL plays a significant role in apoptosis induced by microtubule-damaging drugs. Upon exposure to such drugs, FasL is rapidly expressed. Antibody to FasL inhibits paclitaxel-induced apoptosis. In cells overexpressing Bcl-2, FasL expression is blocked upon exposure to low doses of paclitaxel. The mechanism by which Bcl-2 inhibits FasL expression is indirect; Bcl-2 binds to calcineurin and inhibits its dephosphorylation and release of NFAT. Thus, NFAT is unable to translocate to the nucleus and FasL transcription does not occur. These results suggest a mechanism by which Bcl-2 acts to block drug- or activation-induced apoptosis. Very high doses of paclitaxel can overcome the inhibitory effects of Bcl-2 on NFAT nuclear translocation. High doses of paclitaxel lead to Bcl-2 phosphorylation and dissociation from calcineurin, which allows NFAT activation and FasL expression.

## Materials and Methods

**Reagents.** Paclitaxel, vincristine, vinblastine, ascomycin, and 6-diamidino-2-phenylindole (DAPI) were purchased from Sigma

Chemical Co. Secondary antibody (donkey anti-goat IgG) conjugated with Alexa-488 and 1,2-bis(*o*-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid tetra(acetoxymethyl)ester (BAPTA-AM) were purchased from Molecular Probes, Inc. and Calbiochem Corp., respectively. Antibodies against Bcl-2,  $\beta$ -actin, Fas, and FasL were purchased from Transduction Labs. FasL-neutralizing antibody was purchased from PharMingen. Fas-blocking antibody was purchased from Alexis. Antibody against NFAT was purchased from Santa Cruz Biotechnology. Enhanced chemiluminescent Western blot detection reagents were purchased from Amersham Life Sciences, Inc. The chemiluminescent reporter gene assay system for the combined detection of luciferase and  $\beta$ -galactosidase was purchased from Tropix, Inc.

**Cells and Culture Conditions.** Jurkat T cells and breast carcinoma MDA-MB-231 and MCF-7 cells were obtained from American Type Culture Collection. Cells were cultured in RPMI 1640 tissue culture medium (BioWhittaker, Inc.) supplemented with 2 mM l-glutamine, 10% fetal bovine serum, and 1% penicillin–streptomycin mixture at 37°C with 5%  $CO_2$ .

**Transfection of Bcl-2 Genes.** Jurkat cells and MDA-MB-231 cells were transfected with wild-type Bcl-2 as described elsewhere (25). The pSFFVneo-Bcl-2, pSFFVneo-Bcl-X<sub>L</sub>, and pSFFV Neo plasmids were provided by Dr. Stanley Korsmeyer (Dana-Farber Cancer Institute, Boston, MA). Jurkat cells (JT/mut CD95) harboring a Fas mutant lacking the cytoplasmic domain were provided by Dr. Gary A. Koretzky (University of Iowa, Iowa City, IA) and described elsewhere (46). MDA-MB-231 cells were also transfected with either pSFFVneo- $\Delta$ BH4 Bcl-2 or pSFFVneo- $\Delta$ loop Bcl-2 plasmid using lipofectine (GIBCO BRL). Transduced cells were selected in RPMI 1640 containing 10% fetal bovine serum and 1 mg/ml G418 (Geneticin; GIBCO BRL) for 1 mo. Clones expressing the highest levels of Bcl-2 were used (data not shown).

For transient transfection, lipofectine reagent was used to transfect the plasmid as per manufacturer's instructions (GIBCO BRL). After transfection, the cells were incubated with complete medium for one additional day. These cells were then used for experiments.

**Subcellular Fractionation.** Nuclear and cytosolic fractions were prepared by resuspending cells in 0.8 ml ice cold buffer A (250 mM sucrose, 20 mM Hepes, 10 mM KCl, 1.5 mM  $MgCl_2$ , 1 mM EDTA, 1 mM EGTA, 1 mM dithiothreitol, 17  $\mu$ g/ml phenylmethylsulfonyl fluoride, 8  $\mu$ g/ml aprotinin, and 2  $\mu$ g/ml leupeptin, pH 7.4). Cells were passed through an ice cold cylindrical cell homogenizer. Cell suspensions were pelleted at 750 *g* for 20 min. Cytoplasmic extract was separated from the pellet. This pellet was resuspended in buffer A, homogenized, and spun at 10,000 *g* for 25 min. The clear supernatant was considered nuclear extract.

**Lysate Preparation.** For Western blot analysis, cells were lysed in a buffer containing 10 mM Tris/HCl, pH 7.6; 150 mM NaCl; 0.5 mM EDTA; 1 mM EGTA; 1% SDS; 1 mM sodium orthovanadate; and a mixture of protease inhibitors (1 mM phenylmethylsulfonyl fluoride, 1  $\mu$ g/ml pepstatin A, and 2  $\mu$ g/ml aprotinin). The lysates were then sonicated for 10 s and centrifuged for 20 min at 1,200 *g*. The supernatants were used to perform SDS-PAGE or stored at  $-70^\circ C$ .

**Apoptosis.** For detection of apoptotic cells, the cells were first washed twice with ice cold PBS and then fixed with 1% paraformaldehyde for 30 min. The fixed cells were washed again with PBS and stained with 1  $\mu$ g/ml DAPI solution for 30 min. The apoptotic cells were examined under a fluorescence microscope. Fluorescent nuclei were screened for normal morphology (unaltered chromatin), and apoptotic nuclei comprising those with


fragmented (scattered) and condensed chromatin were counted. Data are expressed as the percentage of apoptotic cells in total counted cells.

**Confocal Microscopy.** For the determination of NFAT translocation by confocal microscope imaging (Axiovert 100; Carl Zeiss, Inc.), cells from each group were seeded onto glass slides and treated with paclitaxel for 48 h. At the end of the incubation period, cells were fixed with 1% paraformaldehyde and 0.01% Triton X-100. Cells were incubated with propidium iodide (PI; 2  $\mu\text{g}/\text{ml}$ ) containing RNase for 1 h and subsequently with anti-NFAT antibody (goat anti-human IgG; 2  $\mu\text{g}/\text{ml}$ ) for 1 h. After incubation, cells were washed three times and restained with secondary antibody (donkey anti-goat IgG) conjugated with Alexa-488 for 1 h. After mounting, cells were visualized for NFAT translocation (Alexa; emission 488 nm and excitation 520 nm) and nuclear fragmentation (PI; emission 540 nm and excitation 610 nm). The green and red colors represent cytoplasmic NFAT and nuclear staining, respectively. The yellow color represents NFAT translocated to the nucleus (red plus green) (see Fig. 4).

## Results

**FasL Is Involved in Paclitaxel-induced Apoptosis.** FasL induction has been demonstrated in activation-induced cell death

in T cells (47–51) and in the death of other cell types induced by anticancer drugs (52), gamma irradiation (53), and UV light (54). We investigated the possibility of the involvement of the FasL/Fas pathway in paclitaxel-induced apoptosis. Jurkat cells or MDA-MB-231 cells were stably transfected with either pSSFV-Neo or pSSFV-Bcl-2 expression vector to assess the protective effects of Bcl-2 on paclitaxel-induced apoptosis (Fig. 1, A and B). Treatment of cells with paclitaxel resulted in induction of apoptosis in a dose-dependent manner, and overexpression of Bcl-2 inhibited paclitaxel-induced apoptosis in Jurkat cells (Fig. 1 C). The paclitaxel dose-response curve suggests a 10-fold increase in resistance in cells overexpressing Bcl-2. Neutralization of FasL by treatment of cells with anti-FasL antibody (NOK-2) significantly inhibited paclitaxel-induced apoptosis in both JT/Neo and JT/Bcl-2 cells. Indeed, very little tumor cell death could be documented in Bcl-2-overexpressing Jurkat cells exposed to anti-FasL antibody. To examine the role of Bcl-2 in paclitaxel-induced apoptosis, we used MDA-MB-231 breast cancer cells, which do not express endogenous Bcl-2 (Fig. 1 B). Overexpression of Bcl-2 in MDA cells inhibited paclitaxel-induced apoptosis by greater than two logs (Fig. 1 D). Neutralization of FasL



**Figure 1.** Bcl-2 inhibits paclitaxel-induced apoptosis. (A) Jurkat cells were stably transfected with either pSSFV-Neo or pSSFV-Bcl-2 plasmid. (B) MDA-MB-231 cells were stably transfected with either pSSFV-Neo or pSSFV-Bcl-2 plasmid. (C) Jurkat cells (JT/Neo and JT/Bcl-2) were treated with paclitaxel (0.001, 0.01, and 0.1  $\mu\text{M}$ ) with or without anti-FasL neutralizing antibody (NOK-2; 1  $\mu\text{g}/\text{ml}$ ) for 48 h. Cells were stained with DAPI and visualized under fluorescence microscopy. Cells with fragmented nuclei or condensed chromatin were counted as apoptotic. Data (mean  $\pm$  SE of quadruplicate determinations) represent one of three separate experiments that gave similar results. (D) MDA-MB-231 (MDA/Neo and MDA/Bcl-2) were treated with paclitaxel (0.001, 0.01, and 0.1  $\mu\text{M}$ ) with or without anti-FasL neutralizing antibody (NOK-2; 1  $\mu\text{g}/\text{ml}$ ) for 48 h. Cells were stained

with DAPI and visualized under fluorescence microscopy. Cells with fragmented and condensed chromatin were counted as apoptotic. Data (mean  $\pm$  SE of quadruplicate determinations) represent one of three separate experiments that gave similar results. (E) JT/Neo and JT/Bcl-2 cells were treated with paclitaxel (0.001, 0.01, and 0.1  $\mu\text{M}$ ) with or without anti-Fas blocking antibody (1  $\mu\text{g}/\text{ml}$ ) for 48 h. Apoptotic nuclei were counted as described for D. (F) JT/Neo and JT/mut CD95 cells were treated with paclitaxel (0.001, 0.01, and 0.1  $\mu\text{M}$ ) for 48 h. Apoptotic nuclei were counted as described for D.

by anti-FasL antibody (NOK-2) significantly inhibited paclitaxel-induced apoptosis in MDA/Neo but had little effect in MDA/Bcl-2 cells. Incubation of cells with Fas-blocking antibody inhibited paclitaxel-induced apoptosis in JT/Neo and JT/Bcl-2 cells. Similarly, overexpression of mutant CD95/Fas (mutant receptors lacking intracellular cytoplasmic domains) inhibited paclitaxel-induced apoptosis (Fig. 1 F). Taken together, these data demonstrate that (a) paclitaxel-induced apoptosis can be inhibited by Bcl-2 and (b) the FasL/Fas pathway, at least in part, mediates paclitaxel-induced apoptosis.


**Bcl-2 Blocks FasL Expression.** The induction of FasL during activation- or drug-induced cell death has been reported (47–52). As neutralization of FasL by anti-FasL antibody inhibited paclitaxel-induced apoptosis, we sought to evaluate the expression of FasL in wild-type and Bcl-2-overexpressing cells. Treatment of wild-type MDA cells with paclitaxel, vincristine, or vinblastine induced FasL expression in a time-dependent manner (Fig. 2 A). Treatment of breast cancer cells (MDA and MCF-7) with paclitaxel resulted in induction of FasL in a dose-dependent manner (Fig. 2 B). We have previously demonstrated that Bcl-2 inhibits apoptosis induced by microtubule-damaging drugs (paclitaxel, vincristine, and vinblastine) (25); therefore, it was of interest to examine whether Bcl-2 would also inhibit FasL expression. Treatment of MDA/Neo cells with 50 nM of paclitaxel or vincristine resulted in induction of FasL; by contrast, the induction of FasL was blocked by overexpression of Bcl-2 in MDA/Bcl-2 cells (Fig. 2 C). JT/Neo cells expressed some FasL at baseline, and paclitaxel induced an increase in FasL expression. The expression of Bcl-2 in JT/Bcl-2 transfectants blocked both the baseline expression and the induction of FasL by paclitaxel

(Fig. 2 D). Thus, Bcl-2 expression interferes with FasL expression.

**Bcl-2 Blocks NFAT Translocation to the Nucleus.** The activation of calcineurin, a serine phosphatase, is regulated by calcium. Activated calcineurin functions to dephosphorylate NFAT family members (45). Dephosphorylated NFAT proteins then translocate to and enter the nucleus, where they serve an essential role in regulating the expression of many cytokine genes (55, 56). As Bcl-2 blocks paclitaxel-induced FasL expression and apoptosis, we examined the effects of Bcl-2 on NFAT translocation to the nucleus. NFAT was localized to the cytoplasm in untreated (control) JT/Neo and JT/Bcl-2 (Fig. 3 A). When JT/Neo cells were treated with paclitaxel, NFAT translocated to the nucleus (Fig. 3 A). In contrast, overexpression of Bcl-2 blocked paclitaxel-induced NFAT translocation to the nucleus (Fig. 3 A). Similarly, overexpression of Bcl-2 blocked paclitaxel-induced NFAT translocation to the nucleus in MDA/Bcl-2 cells (Fig. 3 B).


We confirmed paclitaxel-induced NFAT translocation by confocal microscopy (Fig. 4). We next examined if Bcl-2 would block NFAT translocation to the nucleus in MDA cells by immunocytochemistry. As seen in Fig. 4 B, NFAT was localized to the cytoplasm in MDA/Neo and MDA/Bcl-2 cells (Fig. 4, green). Treatment of MDA/Neo cells with paclitaxel resulted in NFAT translocation to the nucleus (Fig. 4, red plus green = yellow color) and apoptosis (fragmented nucleus stained with red color). As expected, overexpression of Bcl-2 blocked paclitaxel-induced NFAT translocation to the nucleus and apoptosis in MDA cells (Fig. 4).

**Bcl-2 Binds to Calcineurin but not NFAT.** The Bcl-2 inhibition of NFAT translocation to the nucleus is not direct but rather involves calcineurin (57). It has been shown that



**Figure 2.** Bcl-2 inhibits paclitaxel-, vincristine-, and vinblastine-induced FasL expression. (A) MDA cells were treated with 50 nM of paclitaxel, vincristine, or vinblastine for either 24 or 48 h. At the end of incubation period, cells were harvested and lysed. Equal amounts of protein were resolved on SDS-PAGE. FasL levels were measured by Western blot analysis. The same blot was reprobed with anti-β-actin antibody to check if equal amounts of protein were loaded in each lane. (B) MDA and MCF-7 cells were treated with vari-


ous concentrations of paclitaxel for 48 h. FasL levels were detected by Western blot analysis. The blot was reprobed with anti-β-actin antibody to check if equal amounts of protein were loaded in each lane. (C) MDA/Neo and MDA/Bcl-2 cells were treated with 50 nM of paclitaxel or vincristine for 48 h. FasL levels were detected by Western blot analysis. The blot was reprobed with anti-β-actin antibody to check if equal amounts of protein were loaded in each lane. (D) JT/Neo and JT/Bcl-2 cells were treated with paclitaxel (50 nM) for 48 h. FasL levels were detected by Western blot analysis. The blot was reprobed with anti-β-actin antibody to check if equal amounts of protein were loaded in each lane.



**Figure 3.** Bcl-2 blocks NFAT translocation to the nucleus. (A) JT/Neo and JT/Bcl-2 cells were either treated with paclitaxel (50 nM) or vehicle (control) for 48 h. Cells were harvested, and cytoplasmic (C) and nuclear (N) fractions were prepared as described in Materials and Methods. Samples were resolved on SDS-PAGE and immunoblotted with anti-NFAT antibody. The same blot was reprobed with anti- $\beta$ -actin antibody. (B) MDA/Neo and MDA/Bcl-2 cells were either treated with paclitaxel (50 nM) or vehicle for 48 h. Cells were harvested and C and N fractions were prepared as described in Materials and Methods. Samples were resolved on SDS-PAGE and immunoblotted with anti-NFAT antibody. The same blot was reprobed with anti- $\beta$ -actin antibody.

Bcl-2 binds to calcineurin and thereby inhibits translocation of NFAT to the nucleus (57). As the FasL promoter contains NFAT binding sites and NFAT participates in the regulation of FasL expression in activated human T cells (42), it was of interest to examine the intracellular mechanism(s) by which Bcl-2 inhibited paclitaxel-induced FasL

expression. We have previously demonstrated that microtubule-damaging drugs initiated a signaling cascade that phosphorylated Bcl-2 in a time- and dose-dependent manner (25). The JT/Neo and JT/Bcl-2 cells were treated with 50 nM of either paclitaxel or vincristine for 24 h, lysed, immunoprecipitated with anti-NFAT antibody, and blotted




**Figure 4.** Confocal microscopy showing blockage of NFAT translocation by Bcl-2. MDA/Neo and MDA/Bcl-2 cells were treated with paclitaxel (50 nM) for 48 h. Cells were fixed and stained with anti-NFAT antibody along with PI. Cells were washed and restained with secondary antibody conjugated with Alexa-488. Green and red represent cytoplasmic NFAT and nuclear staining, respectively. Yellow, NFAT translocated to the nucleus.

with anti-Bcl-2 antibody (Fig. 5 A). These results indicated that NFAT did not bind to Bcl-2 in either JT/Neo or JT/Bcl-2 cells. When the NFAT immunoprecipitate was followed by NFAT Western blot, similar amounts of NFAT were immunoprecipitated (Fig. 5 A). Therefore, the apparent lack of association of NFAT and Bcl-2 is not related to inefficient NFAT immunoprecipitation. We next examined the interaction between Bcl-2 and calcineurin in paclitaxel- or vincristine-treated JT/Neo and JT/Bcl-2 cells. Cells were exposed to paclitaxel or vincristine for 48 h and then lysed. Lysates were immunoprecipitated with antibody to either Bcl-2 (Fig. 5 B) or calcineurin (Fig. 5 C), and Western blots were performed with the antibody not used in the immunoprecipitation. As shown in Fig. 5 B and C, Bcl-2 was able to bind calcineurin in untreated JT/Neo and JT/Bcl-2 cells. When JT/Neo and JT/Bcl-2 cells

were treated with paclitaxel (50 nM) or vincristine (50 nM), less calcineurin was bound to Bcl-2 (Fig. 5, B and C). These results suggest that Bcl-2 binds to calcineurin but not to NFAT, and the fraction of Bcl-2 and calcineurin bound to each other decreases upon exposure to the drugs. These results suggest that the phosphorylation of Bcl-2 stimulated by the drugs may also influence Bcl-2 binding to calcineurin just as it affects Bcl-2-Bax interaction (25).

The immunosuppressants cyclosporin and FK506 inhibit NFAT-dependent transcriptional events by binding calcineurin and blocking its enzymatic activity, thus preventing the redistribution of NFAT to the nucleus (36). To evaluate the involvement of active calcineurin in paclitaxel-induced apoptosis, cells were treated with the FK506 analogue ascomycin (Fig. 5 D). Paclitaxel induced apoptosis in both JT/Neo and MDA/Neo cells (Fig. 5 D). If Bcl-2





**Figure 5.** Bcl-2 binds to calcineurin but not NFAT. (A) JT/Neo and JT/Bcl-2 cells were treated with 50 nM of paclitaxel or vincristine for 48 h. The cell lysates were prepared and immunoprecipitated with 10 μg of anti-NFAT antibody and 20 μl of protein A-Sepharose. The samples were resolved on SDS-PAGE and immunoblotted with either anti-Bcl-2 antibody (top panel) or anti-NFAT antibody (bottom panel). (B) JT/Neo and JT/Bcl-2 cells were treated with 50 nM of paclitaxel or vincristine for 48 h. The cell lysates were prepared and immunoprecipitated with 10 μg of anti-Bcl-2 antibody and 20 μl of protein A-Sepharose. The samples were resolved on SDS-PAGE and immunoblotted with anticalcineurin. (C) JT/Neo and JT/Bcl-2 cells were treated with 50 nM of paclitaxel or vincristine for 48 h. The cell lysates were prepared and immunoprecipitated with 10 μg of anticalcineurin antibody and 20 μl of protein A-Sepharose. The samples were resolved on SDS-PAGE and immunoblotted with anti-Bcl-2 antibody. (D) Left, JT/Neo and JT/Bcl-2 cells were treated with various concentrations of paclitaxel (0.001, 0.01, and 0.1 μM) with or without FK506 analogue ascomycin (10 μM) for 48 h to measure apoptosis. Cells were stained with DAPI and visualized under fluorescence microscopy. Cells with fragmented nuclei or condensed chromatin were counted as apoptotic. Data (mean ± SE of quadruplicate determinations) represent one of three separate experiments that gave similar results. Right, MDA/Neo and MDA/Bcl-2 cells were treated with various concentrations of paclitaxel (0.001, 0.01, and 0.1 μM) with or without FK506 analogue ascomycin (10 μM) for 48 h to measure apoptosis. Cells were stained with DAPI and visualized under fluorescence microscopy. Data (mean ± SE of quadruplicate determinations) represent one of three separate experiments that gave similar results. (E) JT/Neo and JT/Bcl-2 cells were pretreated with [(Ca<sup>2+</sup>)<sub>i</sub>] chelator BAPTA-AM (10 μM) for 45 min and then treated with paclitaxel (50 nM) for 48 h to measure apoptosis. Data (mean ± SE of quadruplicate determinations) represent one of three separate experiments that gave similar results.

was acting to prevent calcineurin activation, its effects should have been mimicked by the pharmacological calcineurin inhibitor cyclosporin. Overexpression of Bcl-2 inhibited paclitaxel-induced apoptosis in these cell lines. As expected, treatment of cells with cyclosporin inhibited paclitaxel-induced apoptosis in neo- and Bcl-2-transfected cells (Fig. 5 D). Cyclosporin appears to inhibit apoptosis additively in Bcl-2-expressing cells. It is possible that cyclosporin has additional effects unrelated to Bcl-2 binding of calcineurin. These data confirm that inhibition of calcineurin activation blocks paclitaxel-induced apoptosis.

Because a rise in intracellular free calcium levels  $[(Ca^{2+})_i]$  is essential for calcineurin activation (56), we sought to examine the effects of chelating intracellular free calcium by BAPTA-AM on paclitaxel-induced apoptosis (Fig. 5 E). JT/Neo and JT/Bcl-2 cells were pretreated with 10  $\mu$ M BAPTA-AM for 45 min and then treated with paclitaxel (50 nM) for 48 h. Overexpression of Bcl-2 significantly inhibited paclitaxel-induced apoptosis. Interestingly, chelation of intracellular free calcium by BAPTA-AM inhibited paclitaxel-

induced apoptosis in JT/Neo and JT/Bcl-2 cells (Fig. 5 E). That paclitaxel induces a rise in  $[(Ca^{2+})_i]$  has been described by others (58) and confirmed by us (data not shown). These data suggest that a rise in  $[(Ca^{2+})_i]$  is required for paclitaxel-induced apoptosis. These results provide additional evidence that paclitaxel-induced apoptosis involves a rise in  $[(Ca^{2+})_i]$ , leading to calcineurin activation, which in turn leads to NFAT translocation and expression of FasL.

*BH4 Domain of Bcl-2 Is Required for Interaction with Calcineurin and Paclitaxel-induced FasL Expression and Apoptosis.* Thus, Bcl-2 blocked NFAT translocation by binding to calcineurin but not directly to NFAT. The BH4 domain of Bcl-2 has been demonstrated to mediate heterodimerization with calcineurin. We wished to use this finding to verify that the antiapoptotic effects of Bcl-2 were related to calcineurin binding. To answer this question, MDA cells were transfected with empty vector (MDA/Neo), wild-type Bcl-2 (MDA/Bcl-2), or  $\Delta$ BH4 Bcl-2 (Bcl-2 lacking  $\Delta$ BH4 domain, MDA/ $\Delta$ BH4 Bcl-2) (Fig. 6 A). Cells were treated with paclitaxel (50 nM) or left untreated (control) (Fig. 6 B).



**Figure 6.** Bcl-2 interacts with calcineurin through its BH4 domain in inhibiting paclitaxel-induced FasL expression and apoptosis. (A) Western blot showing overexpressed wild-type Bcl-2 and  $\Delta$ BH4 Bcl-2 in MDA-MB-231 cells. (B) MDA/Neo, MDA/ $\Delta$ BH4 Bcl-2, and MDA/Bcl-2 cells were treated with paclitaxel (50 nM) for 48 h. Cells were harvested and lysed. FasL expression was detected by Western blot analysis. The same blot was reprobed with anti- $\beta$ -actin antibody. (C) MDA/Neo, MDA/Bcl-2, and MDA/ $\Delta$ BH4 Bcl-2 cells were treated with paclitaxel (50 nM) for 48 h. The cell lysates were prepared and immunoprecipitated with 10  $\mu$ g of anti-calcineurin antibody and 20  $\mu$ l of protein A-Sepharose. The samples were resolved on SDS-PAGE and immunoblotted with anti-Bcl-2 antibody. (D) MDA/Neo, MDA/ $\Delta$ loop Bcl-2, and MDA/Bcl-2 cells were treated with paclitaxel (200 nM) for 48 h. Top panel, cell lysates were run on SDS-PAGE and immunoblotted with anti-Bcl-2 antibody. Bottom panel, cell lysates were immunoprecipitated with anti-Bcl-2 antibody, run on SDS-PAGE, and immunoblotted with anticalseinurin antibody. (E) MDA/Neo, MDA/ $\Delta$ BH4 Bcl-2, MDA/ $\Delta$ loop Bcl-2, and MDA/Bcl-2 cells were

treated with paclitaxel (0.001, 0.01, and 0.1  $\mu$ M) for 48 h to measure apoptosis. Cells were stained with DAPI and visualized under fluorescence microscopy. Data (mean  $\pm$  SE of quadruplicate determinations) represent one of three separate experiments that gave similar results.

Fig. 6 B demonstrates that paclitaxel induced FasL expression in MDA/Neo cells. Overexpression of wild-type Bcl-2 (MDA/Bcl-2), but not  $\Delta$ BH4 Bcl-2, inhibited paclitaxel-induced FasL expression (Fig. 6 B). We next examined the ability of  $\Delta$ BH4 Bcl-2 to bind with calcineurin in MDA cells. MDA/neo, MDA/Bcl-2, and MDA/ $\Delta$ BH4 Bcl-2 cells were treated with paclitaxel, and lysates were immunoprecipitated with anticalcineurin antibody and immunoblotted with anti-Bcl-2 antibody. Fig. 6 C demonstrates that wild-type Bcl-2 can be coimmunoprecipitated with calcineurin, and treatment of cells with low doses of paclitaxel significantly inhibited the Bcl-2–calcineurin interaction. As expected,  $\Delta$ BH4 Bcl-2 was unable to heterodimerize with calcineurin.


As treatment of cells with high doses of paclitaxel causes more complete Bcl-2 phosphorylation, we sought to examine if phosphorylated Bcl-2 can bind to calcineurin. We and others have previously shown that the loop region of Bcl-2 is an important target for regulatory phosphorylation (59, 60). MDA/Neo, MDA/ $\Delta$ loop Bcl-2 (which can not be phosphorylated), and MDA/Bcl-2 cells were treated with 200 nM paclitaxel for 48 h (Fig. 6 D). Treatment of MDA/Bcl-2 cells with high doses of paclitaxel causes phosphorylation of wild-type Bcl-2, whereas paclitaxel has no effect on  $\Delta$ loop Bcl-2 (phosphorylation-deficient mutant) (Fig. 6 D, top panel). In addition, phosphorylated Bcl-2 was unable to bind with calcineurin (Fig. 6 D, bottom panel). By comparison,  $\Delta$ loop Bcl-2 was not phosphorylated by paclitaxel and formed heterodimers with calcineurin. These data suggest that phosphorylation of Bcl-2 is essential for calcineurin to be released from the complex.

Because  $\Delta$ BH4 Bcl-2 was not able to bind with calcineurin, we sought to examine the effects of this mutant on paclitaxel-induced apoptosis. Overexpression of wild-type Bcl-2 in MDA cells significantly inhibited paclitaxel-

induced apoptosis, whereas overexpression of  $\Delta$ BH4 Bcl-2 mutant had only a slight inhibiting effect (Fig. 6 E). In addition, overexpression of  $\Delta$ loop Bcl-2 completely inhibited paclitaxel-induced apoptosis. Taken together, these data suggest that the  $\Delta$ BH4 domain of Bcl-2 plays a significant role in heterodimerizing with calcineurin and inhibiting paclitaxel-induced apoptosis, and the phosphorylation of the Bcl-2 loop domain allosterically interferes with the BH4–calcineurin interaction.

**Bcl-2 Blocks Paclitaxel-induced FasL Promoter Activity.** It has been shown that the FasL promoter contains two NFAT binding sites (42, 43). We next addressed the functional importance of the two NFAT sites for paclitaxel-mediated FasL expression by generating mutations at one or both NFAT binding sites. Two FasL sites were also mutated in the context of the full length, 486-bp FasL reporter so that FasL expression in this system would not kill the cells. Jurkat cells were transfected with the wild-type reporter or double mutant reporter constructs and then left untreated or treated with paclitaxel. As shown in Fig. 7 A, treatment of JT/Neo cells transfected with wild-type FasL reporter resulted in a 10-fold increase in luciferase activity relative to control cells. In contrast, the reporter containing mutations in both NFAT sites exhibited no luciferase production over control in JT/Neo cells (Fig. 7 A). Interestingly, overexpression of the Bcl-2 gene in JT cells (JT/Bcl-2) inhibited wild-type FasL promoter activity in cells treated with paclitaxel. As expected, low levels of luciferase activity were detected in cells transfected with the double NFAT mutant reporter plasmid in JT/Bcl-2 cells (Fig. 7 A).

We next sought to examine the FasL promoter activation in MDA-MB-231 cells that do not express endogenous Bcl-2 protein. Paclitaxel treatment of MDA/Neo cells transfected with wild-type FasL reporter resulted in a 12-fold increase in



**Figure 7.** NFAT sites play important roles in FasL promoter activation. (A) Jurkat cells (JT/Neo and JT/Bcl-2) were transfected with 70  $\mu$ g of the wild-type 486-bp FasL reporter (FasL-486) or a reporter containing mutations in both the distal and proximal NFAT sites (double mutant). Transfectants were left untreated (control) or treated with paclitaxel (100 nM) for 48 h. Cells were lysed and assayed for luciferase activity. Data are expressed as arbitrary luciferase light units and are representative of four independent experiments. Error bars, SE of triplicate samples. (B) MDA/Neo and MDA/Bcl-2 cells were transfected with 70  $\mu$ g of the wild-type 486-bp FasL reporter (FasL-486) or a reporter containing mutations in both the distal and proximal NFAT sites (double mutant). Transfectants were left untreated (control) or treated with paclitaxel (100 nM) for 48 h. Cells were lysed and assayed for luciferase activity. Data are expressed as arbitrary luciferase light units and are representative of four independent experiments. Error bars, SE of triplicate samples.



luciferase activity relative to control cells. In contrast, overexpression of Bcl-2 blocked FasL promoter activation in paclitaxel-treated MDA/Bcl-2 cells (Fig. 7 B). By comparison, low levels of luciferase activity were detected in cells transfected with double NFAT mutant reporter plasmid in MDA/Bcl-2 cells (Fig. 7 A). Collectively, these results indicate that Bcl-2 blocked FasL transcription by inhibiting NFAT activity.

## Discussion

*Involvement of FasL in Apoptosis.* Activation of T cells results in expression of FasL and induction of apoptosis. In comparison to activation-induced FasL expression in T cells, FasL is constitutively expressed in other selected cell types. The identification of FasL expression on cells in immune privileged sites, such as testis (9) and the anterior chamber of the eye (10), has suggested that FasL may be important in tolerance induction and immunosuppression. Indeed, inflammatory cells in the anterior chamber of the eye undergo Fas-mediated apoptosis and show a systemic tolerance to herpes simplex virus (HSV-1) infection (10). In addition to immune cells, expression of FasL on human tumors, including colon (61), hepatocellular carcinoma (62, 63), melanoma (12), and lung carcinoma (13) has been demonstrated; this expression on cancer cells may be involved in induction of apoptosis in Fas-expressing T cells.

Here we have shown that paclitaxel-induced apoptosis in lymphoid and breast tumor cells is mediated at least in part by increased expression of FasL. As Fas is constitutively expressed in most tumor cells, induction of FasL would be an amplification signal for tumor cell apoptosis. FasL-neutralizing antibody nearly completely abrogates apoptosis induced by microtubule poisons such as paclitaxel and vinblastine.

Recent studies have suggested that environmental stress mediated by exposure to gamma irradiation (53), UV light (54), and anticancer drugs such as etoposide or doxorubicin (52) induces upregulation of Fas receptors and ligands, resulting in autocrine or paracrine cell death. However, the level of Fas expression is only one of the factors regulating the susceptibility to Fas-mediated apoptosis (64). Exposure to radiation, anticancer drugs, or other forms of stress may lead to apoptosis, not only by increasing surface expression of Fas, but also by affecting intracellular signaling molecules activated upon Fas ligation. Indeed, numerous drug-resistant cell lines were also found to be resistant to Fas-mediated apoptosis (65). These findings support the hypothesis that apoptosis mediated by both chemotherapeutic agents and physiologic stimuli such as Fas ligation may share common downstream effector molecules.

*Bcl-2 Inhibits NFAT Translocation to the Nucleus by Binding to Calcineurin but not NFAT.* The expression of FasL is inhibited by immunosuppressive agents CsA and FK506 (47, 50, 66, 67), suggesting that the transcription factor NFAT is involved in FasL induction. Our data demonstrate that the FK506 analogue ascomycin inhibits paclitaxel-induced FasL expression and blocks apoptosis. These data suggest that the calcineurin–NFAT pathway is involved in the control of FasL expression and consequent paclitaxel-induced apoptosis.

Current evidence indicates that both nuclear import and export of NFAT can be regulated dynamically (68, 69). In T cells, relatively profound and sustained cytosolic  $Ca^{2+}$  transients, such as those that occur after antigen receptor engagement, appear to be necessary to activate calcineurin and counterbalance the effects of processes that effect nuclear export of NFAT (70). It has recently been suggested that the  $Ca^{2+}$  signals of shorter duration elicited by activation of the  $G_{\alpha_q}$  receptors may preferentially activate the putative negative regulatory processes (71), whereas activation of calcineurin, dephosphorylation of NFAT, and its subsequent nuclear import require  $Ca^{2+}$  transients of longer duration. Recent studies have provided evidence that a nuclear kinase activity is involved in rephosphorylating NFAT and exporting it to the cytosol as a means for terminating its transcriptional activity (72). Although protein kinase A and glycogen synthase kinase 3 have been implicated as the major NFAT kinases in Jurkat T cells, calmodulin-dependent kinases appear to have some NFAT nuclear export activity as well as a heterotopic expression system (70).

We have shown that NFAT regulates the induction of FasL upon paclitaxel treatment in Jurkat T cells and breast cancer cells. It has been demonstrated that the FasL promoter contains two NFAT binding sites (bp –263 to –283 relative to the FasL translation). Furthermore, the ability of a mutation in this NFAT site (within the context of a 486-bp FasL reporter) to prevent reporter activity in lymphocytes illustrates that this response element is critical for the regulated expression of FasL in our studies. In addition to the observation that CsA inhibits expression of FasL (47, 50, 67) in lymphocytes and that NFAT-deficient mice do not inducibly express FasL (73), these results strongly suggest that NFAT transcription factors are critical for the regulation of FasL expression in lymphocytes and breast carcinoma. The induction of FasL reporter expression is blocked by overexpression of Bcl-2.


The comparison of the NFAT binding region of the FasL promoter with IL-2 and TNF- $\alpha$  promoters provides some insight into the regulation of these genes. AP-1 (activator protein 1) binding sequences are adjacent to NFAT sites in the IL-2 promoter (74), whereas the NFAT sites from the FasL promoter do not include any surrounding predicted AP-1 binding sequences. In contrast, the sequence of the FasL promoter NFAT binding site is similar to that of a previously reported NFAT site within the TNF- $\alpha$  promoter (75). Because of the structural and functional similarities between TNF- $\alpha$  and FasL, it is intriguing to speculate that the conserved NFAT regulatory sequences within the promoters of these genes may have arisen from a common ancestral apoptosis-inducing gene.

As FasL plays an important role in control of lymphocyte apoptosis, and, according to our data, drug-induced apoptosis, we have examined the intracellular mechanism of FasL induction in human T cells and breast cancer cells. The mechanism by which Bcl-2 inhibits drug-induced FasL expression and apoptosis is not known. We have demonstrated that Bcl-2 inhibits paclitaxel-induced NFAT translocation to the nucleus through interactions with calcineurin. In-

deed, Bcl-2 does not bind to NFAT directly, as has also been reported by others (57). The BH4 domain of Bcl-2 binds to calcineurin and thereby inhibits the translocation of NFAT. Calcium-dependent phosphorylation of calcineurin is essential for activation of NFAT and subsequent translocation to the nucleus.

The inhibition of paclitaxel-induced NFAT translocation and apoptosis by Bcl-2 may be one of the mechanisms by which Bcl-2 regulates apoptosis. We have previously shown that microtubule-damaging drugs (paclitaxel, vincristine, and vinblastine) induced Bcl-2 phosphorylation and apoptosis. Indeed, phosphorylated Bcl-2 loses its antiapoptotic function and is unable to heterodimerize with the proapoptotic partner Bax. This free Bax itself can induce apoptosis. Therefore, phosphorylation of Bcl-2 may result in at least two events: (a) release of Bax and (b) failure to hold on to or sequester calcineurin.

**Model: Inhibition of Paclitaxel-induced Apoptosis by Bcl-2.** Collectively, these data support a model in which microtubule-damaging drugs such as paclitaxel stimulate an increase in intracellular free  $Ca^{2+}$  that activates calcineurin, which results in NFAT nuclear translocation, FasL expression, and apoptosis (Fig. 8 A). Apoptosis can be blocked either by treatment of cells with anti-FasL antibody (Fig. 1) or by overexpression of Bcl-2. Bcl-2 sequesters calcineurin, which results in blockage of NFAT nuclear translocation, FasL expression, and apoptosis (Fig. 8 B). All of the phosphorylation sites of Bcl-2 are located within the loop region (amino acid 32–80). The loop region deletion mutant Bcl-2 ( $\Delta$ loop Bcl-2) cannot be phosphorylated and does not release calcineurin from the complex after paclitaxel exposure, and it becomes hyperfunctional in inhibiting drug-induced apoptosis. The inhibition of FasL translocation by Bcl-2 can be overcome by treatment of cells with high doses of paclitaxel ( $>100$  nM) (Fig. 8 C). Treatment of cells with high doses of paclitaxel results in inactivation of Bcl-2 through phosphorylation. Phosphorylated Bcl-2 cannot bind calcineurin, and NFAT activation and FasL expression can occur after Bcl-2 phosphorylation.



**Figure 8.** Model for the inhibition of NFAT signaling by Bcl-2. (A) Treatment of cells with paclitaxel results in calcineurin activation, NFAT nuclear translocation, FasL expression, and apoptosis. (B) Unphosphorylated Bcl-2 binds to calcineurin and blocks NFAT nuclear translocation, FasL expression, and apoptosis. (C) Phosphorylation of Bcl-2 results in release of calcineurin from the complex, translocation of NFAT to the nucleus, and induction of FasL expression and apoptosis.

We thank Dr. Charles Filburn for assisting us with confocal microscopy work. We also extend our sincere thanks to Dr. Stanley J. Korsmeyer (Dana-Farber Cancer Institute, Boston, MA) for providing the Bcl-2 expression vector. We are grateful to Dr. Gary Koretzky (University of Iowa, Iowa City, IA) for providing FasL promoter-luciferase constructs and JT/mut CD95 (DD3) cell line.

R.K. Srivastava is a recipient of the National Research Council Fellowship.

Address correspondence to R.K. Srivastava, Laboratory of Immunology, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Dr., Box 9, Baltimore, MD 21224-6825. Phone: 410-558-8480; Fax: 410-558-8284; E-mail: rakeshs@vax.grc.nia.nih.gov

Submitted: 2 February 1999 Revised: 19 May 1999 Accepted: 25 May 1999

## References

1. Watanabe-Fukunaga, R., C.I. Brannan, N.G. Copeland, N.A. Jenkins, and S. Nagata. 1992. Lymphoproliferation disorder in mice explained by defects in Fas antigen that mediates apoptosis. *Nature*. 356:314–317.
2. Leithauser, F., J. Dhein, G. Mechtersheimer, K. Koretz, S. Bruderlein, C. Henne, A. Schmidt, K.M. Debatin, P.H.

- Krammer, and P. Moller. 1993. Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells. *Lab. Invest.* 69:415–429.
3. French, L.E., M. Hahne, I. Viard, G. Radlgruber, R. Zanone, K. Becker, C. Muller, and J. Tschopp. 1996. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. *J. Cell Biol.* 133:335–343.
  4. Rouvier, E., M.F. Luciani, and P. Golstein. 1993. Fas involvement in  $Ca^{2+}$ -independent T cell-mediated cytotoxicity. *J. Exp. Med.* 177:195–200.
  5. Arase, H., N. Arase, and T. Saito. 1995. Fas-mediated cytotoxicity by freshly isolated natural killer cells. *J. Exp. Med.* 181:1235–1238.
  6. Tanaka, M., T. Suda, K. Haze, N. Nakamura, K. Sato, F. Kimura, K. Motoyoshi, M. Mizuki, S. Tagawa, S. Ohga, et al. 1996. Fas ligand in human serum. *Nat. Med.* 2:317–322.
  7. French, L.E., A. Wilson, M. Hahne, I. Viard, J. Tschopp, and H.R. MacDonald. 1997. Fas ligand expression is restricted to nonlymphoid thymic components in situ. *J. Immunol.* 159:2196–2202.
  8. Watanabe-Fukunaga, R., C.I. Brannan, N. Itoh, S. Yonehara, N.G. Copeland, N.A. Jenkins, and S. Nagata. 1992. The cDNA structure, expression, and chromosomal assignment of the mouse Fas antigen. *J. Immunol.* 148:1274–1279.
  9. Bellgrau, D., D. Gold, H. Selawry, J. Moore, A. Franzusoff, and R.C. Duke. 1995. A role for CD95 ligand in preventing graft rejection. *Nature.* 377:630–632.
  10. Griffith, T.S., T. Brunner, S.M. Fletcher, D.R. Green, and T.A. Ferguson. 1995. Fas ligand-induced apoptosis as a mechanism of immune privilege. *Science.* 270:1189–1192.
  11. Strand, S., W.J. Hofmann, H. Hug, M. Muller, G. Otto, D. Strand, S.M. Mariani, W. Stremmel, P.H. Krammer, and P.R. Galle. 1996. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells—a mechanism of immune evasion? *Nat. Med.* 2:1361–1366.
  12. Hahne, M., D. Rimoldi, M. Schroter, P. Romero, M. Schreier, L.E. French, P. Schneider, T. Bornand, A. Fontana, D. Lienard, et al. 1996. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. *Science.* 274:1363–1366.
  13. Niehans, G.A., T. Brunner, S.P. Frizelle, J.C. Liston, C.T. Salerno, D.J. Knapp, D.R. Green, and R.A. Kratzke. 1997. Human lung carcinomas express Fas ligand. *Cancer Res.* 57:1007–1012.
  14. Liu, Q.Y., M.A. Rubin, C. Omene, S. Lederman, and C.A. Stein. 1998. Fas ligand is constitutively secreted by prostate cancer cells in vitro. *Clin. Cancer Res.* 4:1803–1811.
  15. Nagata, S., and P. Golstein. 1995. The Fas death factor. *Science.* 267:1449–1456.
  16. Nagata, S. 1996. A death factor—the other side of the coin. *Behring. Inst. Mitt.* 97:1–11.
  17. Kondo, T., T. Suda, H. Fukuyama, M. Adachi, and S. Nagata. 1997. Essential roles of the Fas ligand in the development of hepatitis. *Nat. Med.* 3:409–413.
  18. Chervonsky, A.V., Y. Wang, F.S. Wong, I. Visintin, R.A. Flavell, C.A. Janeway, Jr., and L.A. Matis. 1997. The role of Fas in autoimmune diabetes. *Cell.* 89:17–24.
  19. Giordano, C., G. Stassi, R. De Maria, M. Todaro, P. Richiusa, G. Papoff, G. Ruberti, M. Bagnasco, R. Testi, and A. Galluzzo. 1997. Potential involvement of Fas and its ligand in the pathogenesis of Hashimoto's thyroiditis. *Science.* 275:960–963.
  20. Ito, M.R., S. Terasaki, J. Itoh, H. Katoh, S. Yonehara, and M. Nose. 1997. Rheumatic diseases in an MRL strain of mice with a deficit in the functional Fas ligand. *Arthritis Rheum.* 40:1054–1063.
  21. Itoh, N., A. Imagawa, T. Hanafusa, M. Waguri, K. Yamamoto, H. Iwahashi, M. Moriwaki, H. Nakajima, J. Miyagawa, M. Namba, et al. 1997. Requirement of Fas for the development of autoimmune diabetes in nonobese diabetic mice. *J. Exp. Med.* 186:613–618.
  22. Hickman, J.A. 1992. Apoptosis induced by anticancer drugs. *Cancer Metastasis Rev.* 11:121–139.
  23. Pietenpol, J.A., N. Papadopoulos, S. Markowitz, J.K. Willson, K.W. Kinzler, and B. Vogelstein. 1994. Paradoxical inhibition of solid tumor cell growth by bcl2. *Cancer Res.* 54:3714–3717.
  24. Haldar, S., A. Basu, and C.M. Croce. 1997. Bcl2 is the guardian of microtubule integrity. *Cancer Res.* 57:229–233.
  25. Srivastava, R.K., A.R. Srivastava, S.J. Korsmeyer, M. Nesterova, Y.S. Cho-Chung, and D.L. Longo. 1998. Involvement of microtubules in the regulation of Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein kinase. *Mol. Cell. Biol.* 18:3509–3517.
  26. McDonnell, T.J., and S.J. Korsmeyer. 1991. Progression from lymphoid hyperplasia to high-grade malignant lymphoma in mice transgenic for the t(14; 18). *Nature.* 349:254–256.
  27. Strasser, A., A.W. Harris, and S. Cory. 1993. E mu-bcl-2 transgene facilitates spontaneous transformation of early pre-B and immunoglobulin-secreting cells but not T cells. *Oncogene.* 8:1–9.
  28. Linette, G.P., J.L. Hess, C.L. Sentman, and S.J. Korsmeyer. 1995. Peripheral T-cell lymphoma in lckpr-bcl-2 transgenic mice. *Blood.* 86:1255–1260.
  29. Veis, D.J., C.M. Sorenson, J.R. Shutter, and S.J. Korsmeyer. 1993. Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. *Cell.* 75:229–240.
  30. Ma, A., J.C. Pena, B. Chang, E. Margosian, L. Davidson, F.W. Alt, and C.B. Thompson. 1995. Bclx regulates the survival of double-positive thymocytes. *Proc. Natl. Acad. Sci. USA.* 92:4763–4767.
  31. Motoyama, N., F. Wang, K.A. Roth, H. Sawa, K. Nakayama, I. Negishi, S. Senju, Q. Zhang, S. Fujii, et al. 1995. Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. *Science.* 267:1506–1510.
  32. Kumar, N. 1981. Taxol-induced polymerization of purified tubulin. Mechanism of action. *J. Biol. Chem.* 256:10435–10441.
  33. Blagosklonny, M.V., P. Giannakakou, W.S. el-Deiry, D.G. Kingston, P.I. Higgs, L. Neckers, and T. Fojo. 1997. Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. *Cancer Res.* 57:130–135.
  34. Rodi, D.J., R.W. Janes, H.J. Sanganee, R.A. Holton, B.A. Wallace, and L. Makowski. 1999. Screening of a library of phage-displayed peptides identifies human bcl-2 as a taxol-binding protein. *J. Mol. Biol.* 285:197–203.
  35. Haldar, S., A. Basu, and C.M. Croce. 1998. Serine-70 is one of the critical sites for drug-induced Bcl2 phosphorylation in cancer cells. *Cancer Res.* 58:1609–1615.
  36. Schreiber, S.L., and G.R. Crabtree. 1992. The mechanism of action of cyclosporin A and FK506. *Immunol. Today.* 13:

- 136–142.
37. Weiss, D.L., J. Hural, D. Tara, L.A. Timmerman, G. Henkel, and M.A. Brown. 1996. Nuclear factor of activated T cells is associated with a mast cell interleukin 4 transcription complex. *Mol. Cell. Biol.* 16:228–235.
  38. Cockerill, G.W., A.G. Bert, G.R. Ryan, J.R. Gamble, M.A. Vadas, and P.N. Cockerill. 1995. Regulation of granulocyte-macrophage colony-stimulating factor and E-selectin expression in endothelial cells by cyclosporin A and the T-cell transcription factor NFAT. *Blood.* 86:2689–2698.
  39. Boss, V., K.L. Abbott, X.F. Wang, G.K. Pavlath, and T.J. Murphy. 1998. The cyclosporin A-sensitive nuclear factor of activated T cells (NFAT) proteins are expressed in vascular smooth muscle cells. Differential localization of NFAT isoforms and induction of NFAT-mediated transcription by phospholipase C-coupled cell surface receptors. *J. Biol. Chem.* 273:19664–19671.
  40. Ho, A.M., J. Jain, A. Rao, and P.G. Hogan. 1994. Expression of the transcription factor NFATp in a neuronal cell line and in the murine nervous system. *J. Biol. Chem.* 269:28181–28186.
  41. Hoey, T., Y.L. Sun, K. Williamson, and X. Xu. 1995. Isolation of two new members of the NF-AT gene family and functional characterization of the NF-AT proteins. *Immunity.* 2:461–472.
  - 41a. Linette, G.P., Y. Li, R.K. Roth, and S.J. Korsmeyer. 1996. Cross talk between cell death and cell cycle progression: Bcl-2 regulates NFAT-mediated activation. *Proc. Natl. Acad. Sci. USA.* 93:9545–9552.
  42. Latinis, K.M., L.A. Norian, S.L. Eliason, and G.A. Koretzky. 1997. Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. *J. Biol. Chem.* 272:31427–31434.
  43. Latinis, K.M., L.L. Carr, E.J. Peterson, L.A. Norian, S.L. Eliason, and G.A. Koretzky. 1997. Regulation of CD95 (Fas) ligand expression by TCR-mediated signaling events. *J. Immunol.* 158:4602–4611.
  44. Holtz-Heppelmann, C.J., A. Algeciras, A.D. Badley, and C.V. Paya. 1998. Transcriptional regulation of the human FasL promoter-enhancer region. *J. Biol. Chem.* 273:4416–4423.
  45. Clipstone, N.A., and G.R. Crabtree. 1992. Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. *Nature.* 357:695–697.
  46. Peterson, E.J., K.M. Latinis, and G.A. Koretzky. 1998. Molecular characterization of a CD95 signaling mutant. *Arthritis Rheum.* 41:1047–1053.
  47. Anel, A., M. Buferne, C. Boyer, A.M. Schmitt-Verhulst, and P. Golstein. 1994. T cell receptor-induced Fas ligand expression in cytotoxic T lymphocyte clones is blocked by protein tyrosine kinase inhibitors and cyclosporin A. *Eur. J. Immunol.* 24:2469–2476.
  48. Alderson, M.R., T.W. Tough, T. Davis-Smith, S. Braddy, B. Falk, K.A. Schooley, R.G. Goodwin, C.A. Smith, F. Ramsdell, and D.H. Lynch. 1995. Fas ligand mediates activation-induced cell death in human T lymphocytes. *J. Exp. Med.* 181:71–77.
  49. Brunner, T., R.J. Mogil, D. LaFace, N.J. Yoo, A. Mahboubi, F. Echeverri, S.J. Martin, W.R. Force, D.H. Lynch, C.F. Ware, et al. 1995. Cell-autonomous Fas (CD95)/Fas-ligand interaction mediates activation-induced apoptosis in T-cell hybridomas. *Nature.* 373:441–444.
  50. Dhein, J., H. Walczak, C. Baumler, K.M. Debatin, and P.H. Kramer. 1995. Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). *Nature.* 373:438–441.
  51. Ju, S.T., D.J. Panka, H. Cui, R. Ettinger, M. el-Khatib, D.H. Sherr, B.Z. Stanger, and A. Marshak-Rothstein. 1995. Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. *Nature.* 373:444–448.
  52. Fulda, S., H. Sieverts, C. Friesen, I. Herr, and K.M. Debatin. 1997. The CD95 (APO-1/Fas) system mediates drug-induced apoptosis in neuroblastoma cells. *Cancer Res.* 57:3823–3829.
  53. Reap, E.A., K. Roof, K. Maynor, M. Borrero, J. Booker, and P.L. Cohen. 1997. Radiation and stress-induced apoptosis: a role for Fas/Fas ligand interactions. *Proc. Natl. Acad. Sci. USA.* 94:5750–5755.
  54. Rehemtulla, A., C.A. Hamilton, A.M. Chinnaiyan, and V.M. Dixit. 1997. Ultraviolet radiation-induced apoptosis is mediated by activation of CD-95 (Fas/APO-1). *J. Biol. Chem.* 272:25783–25786.
  55. Rothenberg, E.V., and S.B. Ward. 1996. A dynamic assembly of diverse transcription factors integrates activation and cell-type information for interleukin 2 gene regulation. *Proc. Natl. Acad. Sci. USA.* 93:9358–9365.
  56. Rao, A., C. Luo, and P.G. Hogan. 1997. Transcription factors of the NFAT family: regulation and function. *Annu. Rev. Immunol.* 15:707–747.
  57. Shibasaki, F., E. Kondo, T. Akagi, and F. McKeon. 1997. Suppression of signalling through transcription factor NF-AT by interactions between calcineurin and Bcl-2. *Nature.* 386:728–731.
  58. Thuret-Carnahan, J., J.L. Bossu, A. Feltz, K. Langley, and D. Aunis. 1985. Effect of taxol on secretory cells: functional, morphological, and electrophysiological correlates. *J. Cell Biol.* 100:1863–1874.
  59. Srivastava, R.K., Q.S. Mi, J.M. Hardwick, and D.L. Longo. 1999. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis. *Proc. Natl. Acad. Sci. USA.* 96:3775–3780.
  60. Chang, B.S., A.J. Minn, S.W. Muchmore, S.W. Fesik, and C.B. Thompson. 1997. Identification of a novel regulatory domain in Bcl-X<sub>L</sub> and Bcl-2. *EMBO (Eur. Mol. Biol. Organ.) J.* 16:968–977.
  61. O'Connell, J., G.C. O'Sullivan, J.K. Collins, and F. Shanahan. 1996. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. *J. Exp. Med.* 184:1075–1082.
  62. Strand, S., and P.R. Galle. 1998. Immune evasion by tumours: involvement of the CD95 (APO-1/Fas) system and its clinical implications. *Mol. Med. Today.* 4:63–68.
  63. Strand, S., W.J. Hofmann, A. Grambihler, H. Hug, M. Volkmann, G. Otto, H. Wesch, S.M. Mariani, V. Hack, W. Stremmel, et al. 1998. Hepatic failure and liver cell damage in acute Wilson's disease involve CD95 (APO-1/Fas) mediated apoptosis. *Nat. Med.* 4:588–593.
  64. Wallach, D., M. Boldin, E. Varfolomeev, R. Beyaert, P. Vandenabeele, and W. Fiers. 1997. Cell death induction by receptors of the TNF family: towards a molecular understanding. *FEBS Lett.* 410:96–106.
  65. Los, M., I. Herr, C. Friesen, S. Fulda, K. Schulze-Osthoff, and K.M. Debatin. 1997. Cross-resistance of CD95- and drug-induced apoptosis as a consequence of deficient activation of caspases (ICE/Ced-3 proteases). *Blood.* 90:3118–3129.
  66. Brunner, T., N.J. Yoo, T.S. Griffith, T.A. Ferguson, and D.R. Green. 1996. Regulation of CD95 ligand expression: a

- key element in immune regulation? *Behring. Inst. Mitt.* 97: 161–174.
67. Brunner, T., N.J. Yoo, D. LaFace, C.F. Ware, and D.R. Green. 1996. Activation-induced cell death in murine T cell hybridomas. Differential regulation of Fas (CD95) versus Fas ligand expression by cyclosporin A and FK506. *Int. Immunol.* 8:1017–1026.
  68. Ruff, V.A., and K.L. Leach. 1995. Direct demonstration of NFATp dephosphorylation and nuclear localization in activated HT-2 cells using a specific NFATp polyclonal antibody. *J. Biol. Chem.* 270:22602–22607.
  69. Timmerman, L.A., N.A. Clipstone, S.N. Ho, J.P. Northrop, and G.R. Crabtree. 1996. Rapid shuttling of NF-AT in discrimination of  $Ca^{2+}$  signals and immunosuppression. *Nature.* 383:837–840.
  70. Beals, C.R., C.M. Sheridan, C.W. Turck, P. Gardner, and G.R. Crabtree. 1997. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3. *Science.* 275:1930–1934.
  71. Boss, V., X. Wang, L.F. Koppelman, K. Xu, and T.J. Murphy. 1998. Histamine induces nuclear factor of activated T cell-mediated transcription and cyclosporin A-sensitive interleukin-8 mRNA expression in human umbilical vein endothelial cells. *Mol. Pharmacol.* 54:264–272.
  72. Shibasaki, F., E.R. Price, D. Milan, and F. McKeon. 1996. Role of kinases and the phosphatase calcineurin in the nuclear shuttling of transcription factor NF-AT4. *Nature.* 382: 370–373.
  73. Hodge, M.R., A.M. Ranger, F. Charles de la Brousse, T. Hoey, M.J. Grusby, and L.H. Glimcher. 1996. Hyperproliferation and dysregulation of IL-4 expression in NF-ATp-deficient mice. *Immunity.* 4:397–405.
  74. Rao, A. 1994. NF-ATp: a transcription factor required for the co-ordinate induction of several cytokine genes. *Immunol. Today.* 15:274–281.
  75. Tsai, E.Y., J. Yie, D. Thanos, and A.E. Goldfeld. 1996. Cell-type-specific regulation of the human tumor necrosis factor alpha gene in B cells and T cells by NFATp and ATF-2/JUN. *Mol. Cell. Biol.* 16:5232–5244.